|AT THE COMPANY||AT GOLIN/HARRIS INTERNATIONAL|
|Robert V. Toni, President & CEO||For Media Info: Julie Gilman: (312) 729-4216|
|J. Blount Swain, CFO||Molly Todd: (312) 729-4179|
FOR IMMEDIATE RELEASE: January 4, 1999
RONALD A. AHRENS JOINS CLOSURE MEDICAL CORPORATION BOARD OF DIRECTORS
Raleigh, NC, January 4, 1999-- CLOSURE Medical Corporation (Nasdaq: CLSR) today announced that Ronald Ahrens, 59, Senior Advisor and retired President of the Consumer Healthcare Group Worldwide for Merck & Company (NYSE:MRK) is joining CLOSURE's Board of Directors.
Mr. Ahrens has over thirty-one years of extensive experience in the pharmaceutical and health care industry, with particular emphasis on the consumer marketplace. As President of its Consumer Healthcare Group Worldwide, he oversaw a period of significant growth for Merck & Company, one of the worldwide leaders in prescription drugs. Mr. Ahrens joined Merck in 1990 as Executive Vice President of Consumer Healthcare Group International.
Prior to joining Merck & Company, Mr. Ahrens was Consumer Group President for North America for Bristol Myers Squibb, (NYSE:BMY), a company he joined in 1985 as President of the Products Division. From 1973 to 1985 he held several senior positions with Richardson Vicks, including President, Vicks Health Care Divison.
Commenting on Mr. Ahrens' appointment, Robert V. Toni, CLOSURE's President and CEO, said, "We are indeed fortunate to have Ronald Ahrens join the CLOSURE Board of Directors, particularly at this time. His insight, knowledge, and broad experience will be invaluable resources for our Company as we introduce a number of new products for the consumer health care market over the next few years."
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina, develops, manufactures and commercializes medical tissue cohesive products based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable tissue cohesive products may be used to replace sutures and staples for certain topical wound closure applications, while its absorbable tissue cohesive products can potentially be used as tissue cohesives for internal wound closure and management. Currently marketed nonabsorbable tissue cohesive products include DERMABOND* topical skin adhesive, which is used to replace sutures and staples for closure of certain lacerations and incisions, OCTYLDENT* cohesive, which is used as an adjunct in the treatment of adult periodontal disease; and the NEXABAND* line of topical cohesives, which are used in veterinary wound closure and management.
* DERMABOND is a trademark of Ethicon, Inc.; OCTYLDENT and NEXABAND are registered Trademarks of CLOSURE Medical Corporation.
To receive CLOSURE’s latest news release and other corporate documents via FAX -- at no cost -- dial 1-800-PRO-INFO. Use the Company’s ticker-CLSR. Or visit the Financial Relations Board's website at www.frbinc.com.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company products; the need for regulatory approval and effects of governmental regulation; technological uncertainties and dependence on market acceptance and marketing partners, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 1997 filed with the Securities and Exchange Commission.